SAN FRANCISCO, Sept. 25, 2025 — Biostar Pharma’s core anticancer drug Utidelone has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pancreatic cancer, marking its third ODD following prior designations for breast cancer brain metastases and gastric cancer.
Science Significance
Utidelone is a next-generation genetically engineered microtubule inhibitor with advantages over traditional taxanes: it shows enhanced anti-tumor activity, broader activity against resistant tumors, lower hematologic toxicity, and the ability to cross the blood-brain barrier. Preclinical models and clinical data in combination with gemcitabine have shown synergistic suppression of pancreatic cancer cells and deeper tumor inhibition compared with standard regimens.
Regulatory Significance
The ODD status provides regulatory incentives such as tax credits, waiver of FDA application fees, and up to 7 years of market exclusivity upon approval. It also can help expedite development and review pathways under U.S. regulations. This is the third distinct ODD granted to Utidelone (after breast metastases and gastric cancer), strengthening its regulatory profile and demonstrating confidence in its broad oncology potential.
Business Significance
Advertisement
With ODD designation, Utidelone is better positioned in oncology markets, adding value to Biostar’s pipeline. This recognition may attract licensing, co-development, or investment interest and enhance the commercial potential of Utidelone across multiple cancer indications. The broader ODD portfolio further diversifies Biostar’s strategic assets.
Patients’ Significance
Pancreatic cancer is notoriously aggressive and hard to treat, with a 5-year survival rate around 10%. Existing treatments are often ineffective due to drug resistance. For patients with pancreatic cancer, especially in advanced or unresectable settings, Utidelone’s improved efficacy and tolerability could offer a new therapeutic option in an area of high unmet need.
Policy Significance
This development spotlights the importance of orphan drug policies and incentives in encouraging innovation for rare or difficult-to-treat cancers. By awarding ODD to oncology candidates, regulators help de-risk investment in high-need areas, ensuring that pharmaceutical efforts target underserved patient populations.
The FDA’s decision to grant Orphan Drug Designation to Utidelone for pancreatic cancer marks a pivotal step for this drug in its oncology pipeline. Backed by strong scientific rationale, regulatory advantages, and significant patient impact potential, this designation enhances its commercial viability and underscores the value of incentives in driving pharmaceutical innovation in cancer.
Source: Biostar Pharma, Inc. Press Release
